GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Vaxxinity Inc (OTCPK:VAXX) » Definitions » Current Ratio

VAXX (Vaxxinity) Current Ratio : 1.89 (As of Dec. 2023)


View and export this data going back to 2021. Start your Free Trial

What is Vaxxinity Current Ratio?

The current ratio is a liquidity ratio that measures a company's ability to pay short-term obligations. It is calculated as a company's Total Current Assets divides by its Total Current Liabilities. Vaxxinity's current ratio for the quarter that ended in Dec. 2023 was 1.89.

Vaxxinity has a current ratio of 1.89. It generally indicates good short-term financial strength.

The historical rank and industry rank for Vaxxinity's Current Ratio or its related term are showing as below:

VAXX's Current Ratio is not ranked *
in the Biotechnology industry.
Industry Median: 3.65
* Ranked among companies with meaningful Current Ratio only.

Vaxxinity Current Ratio Historical Data

The historical data trend for Vaxxinity's Current Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Vaxxinity Current Ratio Chart

Vaxxinity Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23
Current Ratio
0.07 0.91 5.61 3.03 1.89

Vaxxinity Quarterly Data
Dec19 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Current Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 3.03 2.77 2.51 2.15 1.89

Competitive Comparison of Vaxxinity's Current Ratio

For the Biotechnology subindustry, Vaxxinity's Current Ratio, along with its competitors' market caps and Current Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Vaxxinity's Current Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Vaxxinity's Current Ratio distribution charts can be found below:

* The bar in red indicates where Vaxxinity's Current Ratio falls into.


;
;

Vaxxinity Current Ratio Calculation

The current ratio is mainly used to give an idea of the company's ability to pay back its short-term liabilities with its short-term assets.

Vaxxinity's Current Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Current Ratio (A: Dec. 2023 )=Total Current Assets (A: Dec. 2023 )/Total Current Liabilities (A: Dec. 2023 )
=33.23/17.605
=1.89

Vaxxinity's Current Ratio for the quarter that ended in Dec. 2023 is calculated as

Current Ratio (Q: Dec. 2023 )=Total Current Assets (Q: Dec. 2023 )/Total Current Liabilities (Q: Dec. 2023 )
=33.23/17.605
=1.89

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Vaxxinity  (OTCPK:VAXX) Current Ratio Explanation

The current ratio can give a sense of the efficiency of a company's operating cycle or its ability to turn its product into cash. Companies that have trouble getting paid on their receivables or have long inventory turnover can run into liquidity problems because they are unable to alleviate their obligations. Because business operations differ in each industry, it is always more useful to compare companies within the same industry.

Acceptable current ratios vary from industry to industry and are generally between 1 and 3 for healthy businesses.

The higher the current ratio, the more capable the company is of paying its obligations. A ratio under 1 suggests that the company would be unable to pay off its obligations if they came due at that point. While this shows the company is not in good financial health, it does not necessarily mean that it will go bankrupt - as there are many ways to access financing - but it is definitely not a good sign.

If all other things were equal, a creditor, who is expecting to be paid in the next 12 months, would consider a high current ratio to be better than a low current ratio, because a high current ratio means that the company is more likely to meet its liabilities which fall due in the next 12 months.


Vaxxinity Current Ratio Related Terms

Thank you for viewing the detailed overview of Vaxxinity's Current Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Vaxxinity Business Description

Traded in Other Exchanges
N/A
Address
505 Odyssey Way, Merritt Island, FL, USA, 32953
Vaxxinity Inc is a biotechnology company committed to democratizing healthcare across the globe. The company is pioneering a new class of synthetic, peptide-based active immunotherapy medicines aimed at disrupting the existing treatment paradigm for chronic disease, increasingly dominated by monoclonal antibodies, which suffer from prohibitive costs and cumbersome administration. The company's proprietary technology platform has enabled the innovation of novel pipeline candidates designed to bring the efficiency of vaccines to the treatment of chronic diseases, including Alzheimer's, Parkinson's, migraine, and hypercholesterolemia.
Executives
Sumita Ray officer: Chief Legal Officer, Secretary C/O PHARMACYCLICS, INC., 995 EAST ARQUES AVENUE, SUNNYVALE CA 94085
Prime Movers Lab Fund I Lp 10 percent owner P.O. BOX 12829, JACKSON WY 83002
Landon E Ogilvie director 505 ODYSSEY WAY, EXPLORATION PARK FL 32953
Katherine A. Eade director C/O HARVARD BIOSCIENCE, INC., 84 OCTOBER HILL ROAD #10, HOLLISTON MA 01746
James Alan Smith director 505 ODYSSEY WAY, EXPLORATION PARK FL 32953
Gabrielle B Toledano director 209 REDWOOD SHORES PARKWAY, REDWOOD CITY CA 94065
Lou Reese director, officer: Executive Chairman C/O VAXXINITY, INC., 1717 MAIN ST STE. 3388, DALLAS TX 75201
Mei Mei Hu director, 10 percent owner, officer: See Remarks C/O VAXXINITY, INC., 1717 MAIN ST STE. 3388, DALLAS TX 75201
United Biomedical Inc 10 percent owner 25 DAVIDS DR, HAUPPAUGE NY 11788
Dakin Sloss 10 percent owner 126 E 56TH ST, 30TH FLOOR, NEW YORK NY 10022
Peter Powchik director REGENERON PHARMACEUTICALS, INC., 777 OLD SAW MILL RIVER ROAD, TARRYTOWN NY 10591
Jason Pesile officer: See Remarks C/O VAXXINITY, INC., 1717 MAIN ST. STE.3388, DALLAS TX 75201
George R Hornig director 625 MADISON AVE SUITE 10-B, NEW YORK NY 10017
James Chui director C/O VAXXINITY, INC., 1717 MAIN ST STE. 3388, DALLAS TX 75201
Peter Diamandis director 4640 ADMIRALTY WAY, SUITE 500, MARINA DEL REY CA 90292